Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01224145 · ClinicalTrials.gov registry record · Phase 2

Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant Laparoscopic Inguinal or Umbilical Herniorrhaphy

A Phase 2 study of Postoperative Pain and Hernia, sponsored by Innocoll.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target
1
Study location

NCT01224145 is a Phase 2 study of Postoperative Pain and Hernia that has completed, run by Innocoll. The registered enrollment target is 10 participants, below the 231-participant average among 63 other Postoperative Pain trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01224145, a Phase 2 study of Postoperative Pain and Hernia, has completed, sponsored by Innocoll.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This study will assess pain intensity for the first 72 hrs after aggravated movement (cough) following Laparoscopic Inguinal or Umbilical Herniorrhaphy.

Interventions

  • DRUG 5x5cm bupivacaine collagen sponges

Study Locations (1)

Texas

  • Research Concepts - Bellaire

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2011-03-22
Est. Completion 2011-06-20
Phase Phase 2

Sponsor

Innocoll

19 total trials

What the Registry Record Tells You About NCT01224145

The ClinicalTrials.gov registry entry for NCT01224145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 63 other Postoperative Pain trials with a reported enrollment target (96% lower). The listed sponsor is Innocoll, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Postoperative Pain appearing as the primary indexed condition, and to 1 intervention - of which 5x5cm bupivacaine collagen sponges is the first listed.

NCT01224145 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01224145 about?

NCT01224145 is a clinical study titled "Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant Laparoscopic Inguinal or Umbilical Herniorrhaphy". This study will assess pain intensity for the first 72 hrs after aggravated movement (cough) following Laparoscopic Inguinal or Umbilical Herniorrhaphy.

What is the current status of trial NCT01224145?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-03-22. Estimated completion is 2011-06-20.

What conditions does trial NCT01224145 study?

This clinical trial studies the following conditions: Postoperative Pain, Hernia.

What interventions are being tested in trial NCT01224145?

The interventions under investigation include: 5x5cm bupivacaine collagen sponges (DRUG).

Who is sponsoring clinical trial NCT01224145?

This trial is sponsored by Innocoll, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01224145 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.